Summarized by Daily Strand AI from peer-reviewed source
For children battling cancer, the side effects of chemotherapy can be lifelong. Certain treatments, particularly a widely used medication called cisplatin, can damage the inner ear and lead to permanent sensory hearing loss. Because healthy hearing is crucial for a child's education and social development, doctors want to catch this damage as early as possible. If they detect hearing loss quickly, oncologists might be able to switch the patient to a less ear-damaging alternative.
To find the best way to spot this early damage, researchers compared two different types of hearing tests in 83 pediatric cancer patients between the ages of 2 and 19. They looked at the standard method, known as pure tone audiometry, and compared it to a specialized approach called distortion product otoacoustic emission or DPOAE. While the standard test only provided reliable results in 60 out of 153 exams, the DPOAE test yielded informative results 100 percent of the time.
The DPOAE test proved especially good at detecting early hearing loss at ultra-high frequencies. Researchers found that patients treated with cisplatin showed a significant drop in their test levels at these very high pitches, along with unusual increases at lower frequencies. Fortunately, the study also revealed that two other common cancer drugs, carboplatin and vincristine, did not cause substantial hearing damage in this group of patients.
This research offers a clear path forward for protecting the hearing of childhood cancer survivors. By using DPOAE measurements, clinics can reliably detect hearing loss before it progresses to ranges that affect a child's daily conversations. A perfect success rate for the specialized test shows that it is far more feasible for young patients who might struggle to participate in traditional hearing exams. This early warning system gives doctors a precious window of time to adjust medical treatments and preserve a child's quality of life.
It is important to note that these conclusions are based on a single sample of 83 children. Before hospitals worldwide change their standard practice, broader validation across larger trials at multiple medical centers will be necessary. Even with this early-stage caveat, the results strongly suggest that specialized high-frequency tests could soon become a vital protective tool in pediatric cancer care.
Interested in Diagnostics?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.